Stocks Health care OPK
NASDAQ · Health careOpko Health, Inc. (OPK)
Opko Health, Inc. brought in $501.6M of revenue over the twelve months to September 30, 2026, down 8.3% from a year earlier. It posted a net loss of $148.1M. In fiscal 2025 capital spending exceeded operating cash flow by $190.8M. At September 30, 2026 it held $384M in cash against $477.4M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Opko Health, Inc.
- Net worth
- Opko Health, Inc. has a market value (market cap) of $1.3B at the latest share price, and shareholders' equity of $1.1B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $606.9M (-14.9% year on year), with a net loss of $225.7M. Over the 12 months to September 30, 2026: revenue $501.6M, net loss $148.1M.
- Cash flow
- In fiscal 2025 operations used $178.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Opko Health, Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Opko Health, Inc. does
Opko Health, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker OPK.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $606.9M | -$225.7M | -$0.30 | -$190.8M |
| 2024 | $713.1M | -$53.2M | -$0.08 | -$208.5M |
| 2023 | $863.5M | -$188.9M | -$0.25 | -$44.5M |
| 2022 | $1B | -$328.4M | -$0.46 | -$119.8M |
| 2021 | $1.8B | -$30.1M | -$0.05 | $6.2M |
| 2020 | $1.4B | $30.6M | $0.05 | $5.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where OPK ranks in Health care
Latest SEC filings
What Opko Health, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 6, 2026Activist stake changed SCHEDULE 13D/A
- November 4, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 16% to $65.4M versus the same quarter last year; diluted EPS -$0.07 versus $0.03.
- November 4, 2026
- October 15, 2026
- October 2, 2026Other event 8-K
- August 28, 2026Quarterly report (amended) 10-Q/A · period to June 30, 2026Revenue rose 4.3% to $163.6M versus the same quarter last year; diluted EPS -$0.01 versus -$0.19.
- August 28, 2026Quarterly report (amended) 10-Q/A · period to March 31, 2026Revenue fell 17% to $124.2M versus the same quarter last year; diluted EPS -$0.07 versus -$0.10.
- August 14, 2026
- August 7, 2026Activist stake (5% or more) SCHEDULE 13D
- July 27, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 4.3% to $163.6M versus the same quarter last year; diluted EPS -$0.01 versus -$0.19.
Insider trades
What the people running Opko Health, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $24.6K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 5, 2026 | Paganelli John ADirector | Sold | 4,426 | $7.9K |
| November 5, 2026 | Paganelli John ADirector | Soldindirect | 9,175 | $16.7K |
| July 24, 2026 | Rubin Steven DExecutive VP-Administration, Director | Shares withheld for tax | 53,266 | $65K |
| July 24, 2026 | Logal AdamSr. Vice President, CFO | Shares withheld for tax | 53,266 | $65K |
| March 20, 2026 | Paganelli John ADirector | Bought | 10,000 | $11.4K |
| November 21, 2025 | Frost Phillip Md Et AlCEO & Chairman, Director, 10% owner | Boughtindirect | 102,371 | $133.1K |
| November 21, 2025 | Frost Phillip Md Et AlCEO & Chairman, Director, 10% owner | Boughtindirect | 3,894 | $5.1K |
| November 21, 2025 | Frost Phillip Md Et AlCEO & Chairman, Director, 10% owner | Boughtindirect | 89,375 | $118.4K |
Who owns OPK
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Phillip Frost, M.D.13D, may seek influence with 2 related filers | 37.1% | November 15, 2024 |
| Frost Phillip MD ET AL13D, may seek influence with 2 related filers | 34.1% | July 1, 2026 |
| Opko Health, Inc.13D, may seek influence with 3 related filers | 29.6% | August 7, 2026 |
| Rubric Capital Management LP13G, passive with 1 related filers | 6.03% | July 9, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 223 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Rubric Capital Management LP | 47,791,243 | 0 |
| BlackRock, Inc. | 36,978,893 | +746,670 |
| Vanguard Capital Management LLC | 14,968,930 | +469,766 |
| Vanguard Portfolio Management LLC | 14,934,924 | +165,205 |
| Geode Capital Management, LLC | 11,581,027 | +279,526 |
| State Street Corp | 10,309,070 | +807,693 |
| Goldman Sachs Group Inc | 7,035,492 | -639,534 |
| UBS Group AG | 5,006,284 | -1,065,148 |
| Whitefort Capital Management, LP | 4,511,412 | +258,072 |
| Northern Trust Corp | 3,756,163 | +136,817 |
| Highbridge Capital Management LLC | 3,593,925 | new |
| Charles Schwab Investment Management Inc | 3,596,980 | +22,941 |
| Vanguard Fiduciary Trust Co | 2,706,235 | -35,782 |
| AWM Investment Company, Inc. | 2,110,000 | +10,000 |
| Morgan Stanley | 1,975,027 | +778,940 |
| Citadel Advisors LLC | 1,420,922 | -658,625 |
| Washington Growth Strategies LLC | 1,356,124 | 0 |
| Bank of New York Mellon Corp | 1,329,974 | +49,932 |
| Dimensional Fund Advisors LP | 1,267,741 | -292,259 |
| Y.D. More Investments Ltd | 1,257,568 | -41,905 |
Insiders
4 insiders reported holding 224,231,724 shares in total, about $383.4M at the last price.
| Holder | Shares |
|---|---|
| Frost Phillip Md Et AlCEO & Chairman, Director, 10% owner | 216,706,448216,706,448 held indirectly |
| Rubin Steven DExecutive VP-Administration, Director | 6,571,966 |
| Logal AdamSr. Vice President, CFO | 563,396 |
| Paganelli John ADirector | 389,914 |
Questions about OPK
What does Opko Health, Inc. do?
Opko Health, Inc. is a company in the Health care sector, listed on NASDAQ as OPK. Its shares trade on NASDAQ under the ticker OPK.
What is Opko Health, Inc.'s net worth?
Opko Health, Inc. has a market value (market cap) of $1.3B at the latest share price, and shareholders' equity of $1.1B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Opko Health, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $148.1M on revenue of $501.6M.
How much revenue does Opko Health, Inc. make?
Over the twelve months to September 30, 2026 Opko Health, Inc. reported revenue of $501.6M. That is 8.3% less than a year earlier.
When did Opko Health, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the activist stake changed from November 6, 2026.
When is Opko Health, Inc.'s next earnings report?
Opko Health, Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare OPK with
Follow OPK
Get an email when Opko Health, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Opko Health, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.